<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36739569</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2584</ISSN><JournalIssue CitedMedium="Internet"><Volume>55</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>International urology and nephrology</Title><ISOAbbreviation>Int Urol Nephrol</ISOAbbreviation></Journal><ArticleTitle>Persistent inflammation-immunosuppression-catabolism syndrome in patients with systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>1757</StartPage><EndPage>1765</EndPage><MedlinePgn>1757-1765</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11255-023-03479-3</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the clinical characteristics and prognosis of systemic lupus erythematosus (SLE) with persistent inflammation-immunosuppression-catabolism syndrome (PICS).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We retrospectively analyzed patients with SLE who were admitted to the renal intensive care unit (ICU) for over 14&#xa0;days at Jinling Hospital from July 2010 to July 2018. According to the diagnostic criteria of PICS, we divided the SLE patients into a PICS group and a non-PICS group. We performed a multivariate Cox regression analysis on the risk factors for death in these two groups by comparing the clinical features and prognosis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 96 SLE patients met the inclusion and exclusion criteria of this study, including 61 patients in the PICS group and 35 patients in the non-PICS group. The PICS group patients required a longer length of stay in ICU with higher inflammatory indicators (such as C-reactive protein, procalcitonin and interleukin-6) and lower immune levels (such as total, CD3&#x2009;+&#x2009;, CD4&#x2009;+&#x2009;, CD8&#x2009;+&#x2009;and CD20&#x2009;+&#x2009;lymphocytes) compared to the non-PICS group patients (P&#x2009;&lt;&#x2009;0.01). Hemoglobin, platelets, serum creatinine, serum blood urea nitrogen and SLE Disease Activity Index (SLE-DAI) score in the PICS group were lower than those in the non-PICS group (P&#x2009;&lt;&#x2009;0.05), suggesting severe hematological injury in the PICS group and relatively severe renal damage in the non-PICS group. The rates of PICS combined with sepsis, acute respiratory distress syndrome, mechanical ventilation, gram-positive bacteria, gram-negative bacteria, fungi and double infections were higher than those in the non-PICS group (P&#x2009;&lt;&#x2009;0.05). The 3-year survival rate was 50.82% in the PICS group and 85.71% in the non-PICS group. The 3-year renal survival rate was 32.79% in the PICS group and 51.43% in the non-PICS group. Multivariate Cox regression found that the total lymphocyte count during ICU admission was an independent risk factor for death in SLE patients with PICS.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Patients with SLE complicated with PICS had longer ICU stays, a lower level of SLE activity, a higher risk of secondary infection and a significantly lower survival rate than non-PICS patients.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer Nature B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zhe</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0002-2452-6926</Identifier><AffiliationInfo><Affiliation>National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, 305 East Zhongshan Road, Nanjing, 210016, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Weixin</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, 305 East Zhongshan Road, Nanjing, 210016, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, 305 East Zhongshan Road, Nanjing, 210016, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Shutian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, 305 East Zhongshan Road, Nanjing, 210016, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yuchao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, 305 East Zhongshan Road, Nanjing, 210016, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Shijun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, 305 East Zhongshan Road, Nanjing, 210016, Jiangsu, China. lisj8855@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>JD20200820</GrantID><Agency>Special Program of National Clinical Research Center for Kidney Diseases</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int Urol Nephrol</MedlineTA><NlmUniqueID>0262521</NlmUniqueID><ISSNLinking>0301-1623</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007165" MajorTopicYN="N">Immunosuppression Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="Y">Sepsis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chronic critical illness</Keyword><Keyword MajorTopicYN="N">Persistent inflammation&#x2013;immunosuppression&#x2013;catabolism syndrome</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>5</Day><Hour>14</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36739569</ArticleId><ArticleId IdType="pmc">PMC9899504</ArticleId><ArticleId IdType="doi">10.1007/s11255-023-03479-3</ArticleId><ArticleId IdType="pii">10.1007/s11255-023-03479-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Liu ZH, Zhang HT, Liu ZS, et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med. 2015;162(1):18&#x2013;26. doi: 10.7326/M14-1030.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M14-1030</ArticleId><ArticleId IdType="pubmed">25383558</ArticleId></ArticleIdList></Reference><Reference><Citation>Kronbichler A, Brezina B, Quintana LF, et al. Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: a systematic review. Autoimmun Rev. 2016;15(1):38&#x2013;49. doi: 10.1016/j.autrev.2015.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2015.08.010</ArticleId><ArticleId IdType="pubmed">26318215</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang XH, Chen WC, Ren GS, et al. Autologous hematopoietic stem cell transplantation for refractory lupus nephritis. Clin J Am Soc Nephrol. 2019;14(5):719&#x2013;727. doi: 10.2215/CJN.10570918.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.10570918</ArticleId><ArticleId IdType="pmc">PMC6500938</ArticleId><ArticleId IdType="pubmed">30979713</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L, Ren GS, Chen WC, et al. Long-term follow-up of autologous peripheral blood hematopoietic stem cell transplantation for refractory lupus nephritis-a series study of 20 patients. Lupus. 2022;31(13):1586&#x2013;1594. doi: 10.1177/09612033221126848.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033221126848</ArticleId><ArticleId IdType="pubmed">36117428</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang SC, Lai YY, Huang MC, et al. Corticosteroid dose and the risk of opportunistic infection in a national systemic lupus erythematosus cohort. Lupus. 2018;27(11):1819&#x2013;1827. doi: 10.1177/0961203318792352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203318792352</ArticleId><ArticleId IdType="pubmed">30103646</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamas D. Chronic critical illness. N Engl J Med. 2014;370(2):175&#x2013;177. doi: 10.1056/NEJMms1310675.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMms1310675</ArticleId><ArticleId IdType="pubmed">24401058</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentile LF, Cuenca AG, Efron PA, et al. Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care. J Trauma Acute Care Surg. 2012;72(6):1491&#x2013;1501. doi: 10.1097/TA.0b013e318256e000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e318256e000</ArticleId><ArticleId IdType="pmc">PMC3705923</ArticleId><ArticleId IdType="pubmed">22695412</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber MRW, Drenkard C, Falasinnu T, et al. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol. 2021;17(9):515&#x2013;532. doi: 10.1038/s41584-021-00668-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-021-00668-1</ArticleId><ArticleId IdType="pmc">PMC8982275</ArticleId><ArticleId IdType="pubmed">34345022</ArticleId></ArticleIdList></Reference><Reference><Citation>Moghaddam B, Marozoff S, Li LY, et al. All-cause and cause-specific mortality in systemic lupus erythematosus: a population-based study. Rheumatology (Oxford) 2021;61(1):367&#x2013;376. doi: 10.1093/rheumatology/keab362.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab362</ArticleId><ArticleId IdType="pmc">PMC8742828</ArticleId><ArticleId IdType="pubmed">33871600</ArticleId></ArticleIdList></Reference><Reference><Citation>Mira JC, Gentile LF, Mathias BJ, et al. Sepsis pathophysiology, chronic critical illness, and persistent inflammation-immunosuppression and catabolism syndrome. Crit Care Med. 2017;45(2):253&#x2013;262. doi: 10.1097/CCM.0000000000002074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000002074</ArticleId><ArticleId IdType="pmc">PMC5243156</ArticleId><ArticleId IdType="pubmed">27632674</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandell LA, Wunderink RG, Anzueto A, et al. Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(S2):S27&#x2013;S72. doi: 10.1086/511159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/511159</ArticleId><ArticleId IdType="pmc">PMC7107997</ArticleId><ArticleId IdType="pubmed">17278083</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304&#x2013;377. doi: 10.1007/s00134-017-4683-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-017-4683-6</ArticleId><ArticleId IdType="pubmed">28101605</ArticleId></ArticleIdList></Reference><Reference><Citation>Definition Task Force ARDS, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the berlin definition. JAMA. 2012;307(23):2526&#x2013;2533.</Citation><ArticleIdList><ArticleId IdType="pubmed">22797452</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkins RB, Raymond SL, Stortz JA, et al. Chronic critical illness and the persistent inflammation, immunosuppression, and catabolism syndrome. Front Immunol. 2018;9:1511. doi: 10.3389/fimmu.2018.01511.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.01511</ArticleId><ArticleId IdType="pmc">PMC6036179</ArticleId><ArticleId IdType="pubmed">30013565</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang N, Li BQ, Ye B, et al. The long-term quality of life in patients with persistent inflammation-immunosuppression and catabolism syndrome after severe acute pancreatitis: a retrospective cohort study. J Crit Care. 2017;42:101&#x2013;106. doi: 10.1016/j.jcrc.2017.07.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrc.2017.07.013</ArticleId><ArticleId IdType="pubmed">28710987</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu D, Ren JA, Wang GF, et al. Persistent inflammation-immunosuppression catabolism syndrome, a common manifestation of patients with enterocutaneous fistula in intensive care unit. J Trauma Acute Care Surg. 2014;76(3):725&#x2013;729. doi: 10.1097/TA.0b013e3182aafe6b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e3182aafe6b</ArticleId><ArticleId IdType="pubmed">24553541</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng XB, Pan WY, Liu L, et al. Prognosis for hospitalized patients with systemic lupus erythematosus in China: 5-year update of the Jiangsu cohort. PLoS One. 2016;11(12):e0168619. doi: 10.1371/journal.pone.0168619.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0168619</ArticleId><ArticleId IdType="pmc">PMC5193352</ArticleId><ArticleId IdType="pubmed">28030595</ArticleId></ArticleIdList></Reference><Reference><Citation>Boumpas DT, Chrousos GP, Wilder RL, et al. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med. 1993;119(12):1198&#x2013;1208. doi: 10.7326/0003-4819-119-12-199312150-00007.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-119-12-199312150-00007</ArticleId><ArticleId IdType="pubmed">8239251</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun YS, Huang DF, Lin FC, et al. Cytomegaloviral or pneumocystis jiroveci pneumonia increases mortality in systemic lupus erythematosus patients with pulmonary hemorrhage: Evidence from bronchoalveolar lavage fluid. J Rheumatol. 2019;46(3):251&#x2013;258. doi: 10.3899/jrheum.180104.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.180104</ArticleId><ArticleId IdType="pubmed">30504509</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathias B, Delmas AL, Ozrazgat BT, et al. Human myeloid-derived suppressor cells are associated with chronic immune suppression after severe sepsis/septic shock. Ann Surg. 2017;265(4):827&#x2013;834. doi: 10.1097/SLA.0000000000001783.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000001783</ArticleId><ArticleId IdType="pmc">PMC5102824</ArticleId><ArticleId IdType="pubmed">27163951</ArticleId></ArticleIdList></Reference><Reference><Citation>Buttgereit F, Burmester GB, Lipworth BJ. Optimised glucocorticoid therapy: the sharpening of an old spear. Lancet. 2005;365(9461):801&#x2013;803. doi: 10.1016/S0140-6736(05)17989-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(05)17989-6</ArticleId><ArticleId IdType="pubmed">15733723</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong M, Pan TT, Sun NN, et al. Early prediction for persistent inflammation-immunosuppression catabolism syndrome in surgical sepsis patients. Int J Gen Med. 2021;14:5441&#x2013;5448. doi: 10.2147/IJGM.S331411.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJGM.S331411</ArticleId><ArticleId IdType="pmc">PMC8437379</ArticleId><ArticleId IdType="pubmed">34526811</ArticleId></ArticleIdList></Reference><Reference><Citation>Merayo CJ, Gomez MD, Pineirua MA, et al. Lymphopenia as risk factor for development of severe infections in patients with systemic lupus erythematosus: a case-control study. QJM. 2013;106(5):451&#x2013;457. doi: 10.1093/qjmed/hct046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/qjmed/hct046</ArticleId><ArticleId IdType="pubmed">23458779</ArticleId></ArticleIdList></Reference><Reference><Citation>An Y, Zhang HT, Liu ZH. Individualizing therapy in lupus nephritis. Kidney Int Rep. 2019;4(10):1366&#x2013;1372. doi: 10.1016/j.ekir.2019.08.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ekir.2019.08.005</ArticleId><ArticleId IdType="pmc">PMC6829184</ArticleId><ArticleId IdType="pubmed">31701046</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenthal MD, Vanzant EL, Moore FA. Chronic critical illness and PICS nutritional strategies. J Clin Med. 2021;10(11):2294. doi: 10.3390/jcm10112294.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10112294</ArticleId><ArticleId IdType="pmc">PMC8197535</ArticleId><ArticleId IdType="pubmed">34070395</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M. Inflammatory markers in systemic lupus erythematosus. J Autoimmun. 2020;110:102374. doi: 10.1016/j.jaut.2019.102374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2019.102374</ArticleId><ArticleId IdType="pubmed">31812331</ArticleId></ArticleIdList></Reference><Reference><Citation>Warny M, Helby J, Nordestgaard BG, et al. Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study. PLoS Med. 2018;15(11):e1002685. doi: 10.1371/journal.pmed.1002685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1002685</ArticleId><ArticleId IdType="pmc">PMC6211632</ArticleId><ArticleId IdType="pubmed">30383787</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao RQ, Ren C, Zheng LY, et al. Advances in immune monitoring approaches for sepsis-induced immunosuppression. Front Immunol. 2022;13:891024. doi: 10.3389/fimmu.2022.891024.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.891024</ArticleId><ArticleId IdType="pmc">PMC9127053</ArticleId><ArticleId IdType="pubmed">35619710</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao SJ, Hou JH, Xie GT, et al. Improvement of outcomes in patients with lupus nephritis: management evolution in Chinese patients from 1994 to 2010. J Rheumatol. 2019;46(8):912&#x2013;919. doi: 10.3899/jrheum.180145.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.180145</ArticleId><ArticleId IdType="pubmed">30824650</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson A. What is damaging the kidney in lupus nephritis? Nat Rev Rheumatol. 2016;12(3):143&#x2013;153. doi: 10.1038/nrrheum.2015.159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2015.159</ArticleId><ArticleId IdType="pmc">PMC4820834</ArticleId><ArticleId IdType="pubmed">26581344</ArticleId></ArticleIdList></Reference><Reference><Citation>Carli L, Tani C, Vagnani S, et al. Leukopenia, lymphopenia, and neutropenia in systemic lupus erythematosus: prevalence and clinical impact&#x2013;a systematic literature review. Semin Arthritis Rheum. 2015;45(2):190&#x2013;194. doi: 10.1016/j.semarthrit.2015.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2015.05.009</ArticleId><ArticleId IdType="pubmed">26170228</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaitonde S, Samols D, Kushner I. C-reactive protein and systemic lupus erythematosus. Arthritis Rheum. 2008;59(12):1814&#x2013;1820. doi: 10.1002/art.24316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24316</ArticleId><ArticleId IdType="pubmed">19035410</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>